Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Last trade$19.54
Day change-$0.20 (-1.01%)
Day range$19.34 – $20.65
Volume469,620
Market cap$1.36B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.36B
Price / earnings
—
Price / book
1.97×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.99×
Profitability
Earnings per share
-$2.45
Return on assets
-23.3%
Return on equity
-24.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
23.93×
Quick ratio
23.93×
Cash ratio
15.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$119.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TYRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$11.74M
$9.81M
$8.53M
$8.33M
$7.48M
$7.14M
$6.89M
$7.56M
Research and development
$43.14M
$39.2M
$33.47M
$28.19M
$25.47M
$24.31M
$24.96M
$22.18M
Total operating expenses
$54.89M
$49M
$42M
$36.52M
$32.94M
$31.45M
$31.85M
$29.74M
Operating income
-$54.89M
-$49M
-$42M
-$36.52M
-$32.94M
-$31.45M
-$31.85M
-$29.74M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$51.12M
-$45.56M
-$39.31M
-$33.83M
-$29.87M
-$28.1M
-$28.15M
-$25.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$51.12M
-$45.56M
-$39.31M
-$33.83M
-$29.87M
-$28.1M
-$28.15M
-$25.57M
Net income attributable to common shareholders
-$51.12M
-$45.56M
-$39.31M
-$33.51M
-$29.87M
-$28.1M
-$28.15M
-$26.94M
EBITDA
-$54.76M
-$48.87M
-$41.86M
-$36.38M
-$32.81M
-$31.31M
-$31.71M
-$29.6M
Basic earnings per share
-$0.74
-$0.69
-$0.64
-$0.56
-$0.50
-$0.47
-$0.47
-$0.46
Diluted earnings per share
-$0.74
-$0.69
-$0.64
-$0.56
-$0.50
-$0.47
-$0.47
-$0.46
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 study results for dabogratinib. Despite claims of a favorable safety profile, the trial showed Grade 3 adverse events in 9-14% of participants, leading to a 17.66% stock price decline on September 9, 2026.
Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026.
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.
Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.
BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.